Popular weight loss and diabetes drugs show no biological link to mental illness

Medications used to treat diabetes and obesity do not appear to increase the risk of mental health conditions like depression, anxiety, or suicide. A new study combining genetic analysis and real-world clinical data found no evidence tying glucagon-like peptide-1 receptor agonists to psychiatric disorders. The findings were published in the Journal of Affective Disorders.

Glucagon-like peptide-1 is a naturally occurring hormone produced in the intestines. When a person eats, this hormone prompts the pancreas to release insulin to manage blood sugar levels. It also sends signals to the brain to promote a feeling of fullness. Pharmaceutical companies developed synthetic versions of this hormone to help patients manage type 2 diabetes.

These medications are known as glucagon-like peptide-1 receptor agonists. Because they effectively slow digestion and reduce appetite, they have recently gained immense popularity as weight loss treatments. However, as millions of people began taking these drugs, health authorities started receiving troubling reports.

Patients and doctors submitted accounts to the European Medicines Agency and the United States Food and Drug Administration detailing adverse psychiatric events. Some individuals reported experiencing intense anxiety, new depressive symptoms, or suicidal thoughts after starting the injections. Because the drugs interact with brain regions involved in reward and emotional regulation, medical professionals worried about potential psychiatric side effects.

Investigating these reports using standard observational data has proven exceptionally difficult. Patients prescribed these medications usually have chronic conditions like diabetes or clinical obesity. These underlying health issues are already associated with a higher baseline risk for depression and anxiety, making it hard to separate the effects of the disease from the effects of the drug.

Free daily newsletter

Additionally, rapid weight loss itself can cause immense psychological shifts. Some early studies suggested the medications might trigger mental health issues, while other reviews found they actually reduced suicidal ideation compared to alternative treatments. To bypass the limitations of observational research, Chenhao Ouyang, a researcher at Nanchang University in China, and colleagues designed an alternative approach.

The team utilized an epidemiological technique called Mendelian randomization. This method relies on the fact that genetic variations are passed down randomly from parents to children at conception. Because this genetic lottery is unaffected by lifestyle choices or environmental factors, scientists can use it as a natural experiment to help establish cause and effect.

The researchers searched massive genetic databases for specific DNA variations that naturally alter how the body’s glucagon-like peptide-1 receptors function. These genetic tweaks serve as a lifelong proxy for taking the medication. If the biological pathway activated by the weight loss drugs genuinely causes mental health problems, people carrying these specific genetic variations should exhibit higher rates of mental illness.

To conduct the Mendelian randomization analysis, the researchers needed highly specific genetic data. They utilized two layers of biological information to create their genetic proxies. First, they looked at variations altering gene expression, which dictates how actively the body reads the DNA code to produce the receptor. Second, they examined variations affecting the actual abundance of the receptor protein circulating in the body. Finding consistent results across both biological variables helps verify the reliability of the overall conclusions.

The team accessed data from massive international genetics initiatives, including the FinnGen project and the Psychiatric Genomics Consortium. FinnGen alone contains biological samples and health records from over half a million Finnish citizens. The Psychiatric Genomics Consortium involves hundreds of researchers globally and features data from hundreds of thousands of participants, ensuring a robust sample size for detecting rare conditions.

Using these databases, the researchers compared the genetic proxies for receptor activity against the genetic profiles of seven distinct psychiatric conditions. The targeted disorders included anxiety, bipolar affective disorder, chronic depression, major depression, eating disorders, suicide, and schizophrenia.

Applying several statistical models, the investigators looked for overlapping patterns. They tested whether the genes dictating receptor activity and the genes associated with mental illness were inherited together. They also checked for shared genetic architecture across the different traits.

The genetic results showed no connection at all between the biological target of the drugs and the psychiatric conditions. Natural variations in the receptor did not alter a person’s risk for any of the seven mental health disorders. The researchers found no shared causal variants driving both the receptor’s function and the occurrence of mental illness.

To test these genetic findings against physical practice, Ouyang and the research team also conducted a wide-ranging review of existing clinical data. They performed a meta-analysis, which is a statistical process that combines the results of multiple independent studies to identify broader trends. They gathered thirty-five prior studies that documented real-world mental health outcomes in patients.

This pooled data compared individuals taking the medications to control groups receiving alternative treatments or placebos. The clinical review mirrored the genetic analysis perfectly. Patients taking the weight loss and diabetes medications did not have a statistically significant difference in rates of anxiety, depressive symptoms, or suicidal behavior.

The researchers did find one exception in the clinical data, specifically regarding eating disorders. Patients using the medications showed noticeable improvements in eating disorder symptoms compared to those not taking the drugs. The authors suggest this could occur because the medications influence the brain’s reward centers to reduce the frequency and severity of binge eating behaviors.

Despite the reassuring results, the investigators noted several limitations to their work. Their analysis of the clinical data did not separate patients who had a prior history of mental illness from those without such a background. Making this distinction in future studies might help researchers better understand why isolated reports of depression or suicide still occur in some patients.

The genetic data utilized in the study predominantly came from individuals of European descent. This focus means the results might not perfectly translate to other global populations with different genetic backgrounds. The project also did not look at how varying medication doses might influence psychological health over extended periods.

The available genetic data for the receptor was somewhat sparse, which can sometimes lead to unstable statistical estimates. The authors recommend future prospective clinical trials to track mental health outcomes over time in diverse populations. They specifically highlight the need for research focusing on subgroups like patients with pre-existing binge eating disorders to verify the potential benefits observed in this review.

Overall, the combined genetic and real-world results offer theoretical support for the psychological safety of these widely used treatments. The biological mechanisms that make the drugs effective for metabolic conditions do not appear to inherently drive psychiatric distress.

The study, “Causal association between glucagon-like peptide-1 receptor agonists and mental disorders: insight from genetic and real-world evidence,” was authored by Chenhao Ouyang, Xiaoyue Zhang, Minhai Zhang, Yan Miao, Zicheng Zhu, Yunting Zeng, Hong Ban, Yuting Wu, Nanqin Peng, Jitao Ling, Chen Li, Deju Zhang, Peng Yu, Jing Zhang, Xiao Liu, and Tongsheng Huang.